Table 1.

Selected studies on the therapeutic effect of MSCs in the clinical application of ALI/ARDS.

Author	Publication time	MSCs source	Results	Reference
Shi et al.	2021	Human umbilical cord (UC)-derived MSCs	Improvement in whole lung lesion and improved restoration of the integrated reserve capability of patients. No significant improvement in lymphocyte count subpopulations, oxygen therapy status, or mMRC dyspnea score in patients	[8]
Shi et al.	2022	Human UC-MSCs	UC-MSCs improved total lung lesions in severe COVID-19 patients, restored pulmonary reserve capacity, and did not affect the production and maintenance of neutralizing antibodies in patients.	[16]
Lanzoni G et al.	2021	Human UC-MSCs	UC-MSCs reduced the levels of inflammatory factors such as GM-CSF, IFNg, IL-5, IL-6, IL-7, TNFa, TNFb, PDGF-BB and improved the survival of ARDS patients	[17]
Monsel A et al.	2022	Human UC-MSCs	No significant between-group secondary-endpoint differences were observed for SOFA scores, PaO2/FiO2 ratios, compliance, organ-failure–free days, ventilation-free days, duration of ventilation. Later decreases of inflammatory markers in the UC-MSCs-treated group were the only significant difference found	[18]
Kaffash Farkhad N et al.	2022	Human UC-MSCs	Intravenous UC-MSCs significantly improved SPO2/FiO2 and the levels of serum CRP, IL-6, IFN-g, TNF-α, and IL-17A. No significant changes were observed in CT scan images of patients during the study period.	[19]